Minerva Neurosciences up on filing marketing application for mental disorder drug

Minerva Neurosciences

01/05/2023 14:04

** Shares of drug developer Minerva Neurosciences Inc
 NERV.O  jump 25% to $3.50 premarket
    ** Company says it has filed marketing application with U.S.
FDA for its experimental drug to treat negative symptoms of
schizophrenia
    ** FDA in October had rejected NERV's previous application
saying it did not meet the compliance needs of the health
regulator
    ** Company said the agency has agreed the reason cited for
rejecting its previous application should be considered during
FDA's review of the latest application
    ** Schizophrenia is a chronic mental illness, characterized
by distortions in thinking, perception, emotions, language,
sense of self and behavior
    ** Up to Friday's close, stock up 76% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))